Coeptis Therapeutics Company Insiders
| COEP Stock | USD 11.06 0.61 5.84% |
Coeptis Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Coeptis Therapeutics suggests that virtually all insiders are extremely bullish. Coeptis Therapeutics employs about 5 people. The company is managed by 6 executives with a total tenure of roughly 12 years, averaging almost 2.0 years of service per executive, having 0.83 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-01-12 | Tara Desilva | Acquired 113 @ 11.6 | View | ||
| 2024-01-10 | Brian Cogley | Acquired 250 @ 13.4 | View | ||
| 2024-01-08 | David Mehalick | Acquired 1000 @ 13.2 | View | ||
| 2024-01-05 | Gene Salkind | Acquired 580 @ 13.8 | View | ||
| 2023-08-29 | Gene Salkind | Acquired 200 @ 20.2 | View | ||
| 2023-08-25 | Gene Salkind | Acquired 1431 @ 18.2 | View | ||
| 2023-08-23 | Chris Calise | Acquired 579 @ 18.8 | View |
Monitoring Coeptis Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Coeptis |
Coeptis Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.8735) % which means that it has lost $1.8735 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8129) %, meaning that it created substantial loss on money invested by shareholders. Coeptis Therapeutics' management efficiency ratios could be used to measure how well Coeptis Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/14/2025, Return On Tangible Assets is likely to grow to -11.52. In addition to that, Return On Capital Employed is likely to grow to -14.84. As of 03/14/2025, Non Current Liabilities Total is likely to grow to about 1.1 M, while Total Current Liabilities is likely to drop slightly above 2.3 M.As of 03/14/2025, Common Stock Shares Outstanding is likely to drop to about 14.6 M. In addition to that, Net Loss is likely to grow to about (32.1 M)
Coeptis Therapeutics Workforce Comparison
Coeptis Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,073. Coeptis Therapeutics adds roughly 5.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Coeptis Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coeptis Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coeptis Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Coeptis Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 9.0 | 9 | 1 | 61,770 | 0.00 |
| 2022-12-01 | 1.0 | 3 | 3 | 9,000,000 | 0.00 |
Coeptis Therapeutics Notable Stakeholders
A Coeptis Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Coeptis Therapeutics often face trade-offs trying to please all of them. Coeptis Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Coeptis Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Christine Sheehy | CoFounder Secretary | Profile | |
| Daniel Yerace | VP CoFounder | Profile | |
| Gary Conte | VP Marketing | Profile | |
| David Mehalick | Chairman, CoFounder | Profile | |
| Brian MBA | Chief Officer | Profile | |
| MSc MD | CSO Officer | Profile |
About Coeptis Therapeutics Management Performance
The success or failure of an entity such as Coeptis Therapeutics often depends on how effective the management is. Coeptis Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Coeptis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Coeptis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (12.13) | (11.52) | |
| Return On Capital Employed | (15.62) | (14.84) | |
| Return On Assets | (5.35) | (5.08) | |
| Return On Equity | (5.67) | (5.95) |
Coeptis Therapeutics Workforce Analysis
Traditionally, organizations such as Coeptis Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Coeptis Therapeutics within its industry.Coeptis Therapeutics Manpower Efficiency
Return on Coeptis Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4.3M | |
| Net Loss Per Executive | 3.5M | |
| Working Capital Per Employee | 452.2K | |
| Working Capital Per Executive | 376.8K |
Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.